Skip to main content

Biosimilars

Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach

How can modelling and simulation optimize the clinical development of adalimumab biosimilar candidates?

In the context of the 7th European Biosimilars Congress, held in Munich 15-16 May 2017, Bernardo de Miguel Lillo presented an abstract and a poster about how we optimized the clinical development of an Adalimumab biosimilar candidate thanks to modelling and simulation.

How can modelling and simulation optimize the clinical development of biosimilars?

Bernardo de Miguel Lillo explores the competitive advantages SGS Exprimo can offer in the development of biosimilars

How can we help you?